TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04436406

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [99mTc]-NM-01 SPECT/CT
Description: Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
Study: NCT01731600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
Study: NCT04252560

Intervention type: PROCEDURE
Intervention: Colectomy, CRS+HIPEC
Description: No special interventions are going to be performed. Fecal samples are going to be taken and analysed

Intervention type: PROCEDURE
Intervention: Colectomy, CRS+HIPEC
Description: No special interventions are going to be performed. Fecal samples are going to be taken and analysed
Study: NCT01329822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction
Study: NCT01201291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normobaric oxygen
Description: Fraction of inspired oxygen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normobaric oxygen
Description: Fraction of inspired oxygen
Study: NCT03348644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphate tablets.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High cheese intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High milk intake.
Study: NCT02918136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived regenerative cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injectable
Study: NCT04539444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/22 CART
Description: CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive Tislelizumab 200mg/dose every 3 weeks.
Study: NCT04555993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower abdominal surgery
Description: Patients will undergo lower abdominal surgery under general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower abdominal surgery
Description: Patients will undergo lower abdominal surgery under general anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
Study: NCT01359813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin
Description: Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
Study: NCT01903096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Treatment As Usual
Description: Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
Study: NCT01679964

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir switch
Description: Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
Study: NCT02934464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX 6
Study: NCT03305705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9%
Description: Single intravenous infusion of 250 ml within 20 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 0.9%
Description: Single intravenous infusion of 250 ml within 20 min
Study: NCT01000207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Description: High dose group and low dose group of adjuvanted vaccines
Study: NCT02556268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose
Study: NCT01840098

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low leucine content drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high leucine content drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low leucine + HMB drink
Study: NCT00827294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
Study: NCT01760005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Subcutaneously every 4 weeks at escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Intravenous infusion every 4 weeks at escalating doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Gantenerumab)
Description: Subcutaneous injection of placebo every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Solanezumab)
Description: Intravenous infusion of placebo every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gantenerumab
Description: Open-label administered Subcutaneously every 4 weeks at escalating doses
Study: NCT01840098

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control/carbohydrate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 36 hour fasting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 36 hour fasting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 36 hour fasting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 36 hour fasting
Study: NCT04041245

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.
Study: NCT00638976

Intervention type: DRUG
Group type: OTHER
Intervention: eptifibatide
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
Study: NCT00483002

Intervention type: DRUG
Intervention: varenicline
Description: As prescribed by physician in usual clinical practice.
Study: NCT01760005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: Administered intravenously in a blinded fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (E2814)
Description: Placebo administered intravenously in a blinded fashion.
Study: NCT02556268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg, Oral (fasted conditions), 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA
Description: 600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMPLERA
Description: 200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRIBILD
Description: 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIUMEQ
Description: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral protease inhibitor
Description: Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
Study: NCT01135758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
Study: NCT01829555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
Study: NCT05328128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toilet training
Description: As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
Study: NCT03147586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bio-tech and omega-3 plus
Description: immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03799809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrabronchial Voriconazole instillation
Description: Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
Study: NCT01282645

Intervention type: DEVICE
Intervention: PSI in PEEK
Description: A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
Study: NCT05301296

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination of the breast for early detection of Cancer
Description: Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
Study: NCT02256761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX - multiple escalating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX - single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high caloric meal
Description: 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
Study: NCT04327232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Mineralocorticoid Receptor Antagonists

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT02002923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
Study: NCT02092662

Intervention type: OTHER
Intervention: stroke
Description: task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context

Intervention type: OTHER
Intervention: Healthy controls
Description: no treatment
Study: NCT00530933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation
Description: Once weekly for 30 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: 30 minutes once weekly

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous tibial nerve stimulation
Description: Once weekly for 30 minutes
Study: NCT03573947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
Study: NCT03777007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPARTA force plate
Description: The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
Study: NCT00885755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard taxane therapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
Study: NCT02193373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Medicine
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Medicine
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Medicine
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Medicine
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Osteopathic Manual Medicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Osteopathic Manual Medicine
Study: NCT01266460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05600439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareME
Description: CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision.
Study: NCT03566121

Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic ultrasound / Urodynamic ultrasound
Description: Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound / Urodynamic ultrasound
Description: Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
Study: NCT03839758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA standard
Description: Glenoid preparation will be done with 2D CT-Scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RTSA standard
Description: Glenoid preparation will be done with 2D CT-Scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA Blueprint
Description: Glenoid preparation will be done with Blueprint software

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RTSA Blueprint
Description: Glenoid preparation will be done with 2D CT-Scan